18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. - Wikidata - awgldk - TriplyDB

18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.

18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.

http://www.wikidata.org/entity/Q37918311

about

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status How we read FCH-PET/CT for prostate cancer Clinical applications of PET/MRI: current status and future perspectives.Molecular Imaging of Prostate Cancer GCPII imaging and cancer.Positron emission tomography (PET) in primary prostate cancer staging and risk assessment Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer A system for MRI-guided transperineal delivery of needles to the prostate for focal therapy.Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone Combined PET imaging and diffusion-weighted imaging of intermediate and high-risk primary prostate carcinomas with simultaneous [18F] choline PET/MRI Prognostic Utility of PET in Prostate Cancer.Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer.Functional imaging for prostate cancer: therapeutic implications.Molecular imaging of prostate cancer: PET radiotracers.Optimization of Acquisition time of 68Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer.The dog prostate cancer (DPC-1) model: a reliable tool for molecular imaging of prostate tumors and metastases.Positron Emission Tomography in Prostate Cancer: Summary of Systematic Reviews and Meta-Analysis.Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.Controversies on individualized prostate cancer care: gaps in current practice.Translational Molecular Imaging of Prostate Cancer.Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT Molecular imaging of urogenital diseases.Quantitative 18F-fluorocholine positron emission tomography for prostate cancer: correlation between kinetic parameters and Gleason scoring.The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review.PET imaging in prostate cancer: focus on prostate-specific membrane antigen Individualized image-based lymph node irradiation for prostate cancer.Imaging and evaluation of patients with high-risk prostate cancer.PET imaging of recurrent and metastatic prostate cancer with novel tracers.Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers.PET imaging for lymph node dissection in prostate cancer.2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.Results of combined radiotherapy and hormonal treatment of prostate cancer patients with initial PSA value >40 ng/ml.A fully-automated one-pot synthesis of [18F]fluoromethylcholine with reduced dimethylaminoethanol contamination via [18F]fluoromethyl tosylate.Phase IIa Clinical Trial of Trans-1-Amino-3-(18)F-Fluoro-Cyclobutane Carboxylic Acid in Metastatic Prostate Cancer.Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.

P2860

Q26774920-4146679A-64DB-4626-BDDF-CD2C8B938FD0 Q28077447-9DF2DDBC-3ABF-4CDD-B314-1F9A982DE9BB Q30835897-F50FE0F4-9FA8-41B7-AAFF-F3E2134498E6 Q33620520-DE08BDBA-83CC-4FBB-B308-E8B9FDE1AD49 Q33827632-3A54AC5E-352A-472C-A94D-7BB6CD26F44B Q33890153-70AA2587-10CE-47FF-9F3C-58B67E82C8FA Q34465066-1622DF12-F64F-43A9-93FB-7BFA5CCD2E5C Q34539189-6151D281-D8CF-4922-BCC8-553A40E1BEC3 Q35068005-465C7029-0444-43FB-9C95-B31EABCF262C Q35208318-AB1583A2-9376-4319-8099-48BE5B6D3B76 Q35244433-15714A9A-3345-4AB4-B718-F87F908CB3A6 Q35515150-F2BA8A32-96B8-4C96-9028-4B501363B0A5 Q35544056-445FDA31-0020-44AB-8D33-1BEBA0418E08 Q35582133-701A7687-1D66-4F4C-BB4E-5B280F8C2E8D Q36128629-01174849-6CEB-447B-BC1A-7751F868D889 Q36129937-2430D079-AAC4-4BE3-8EDC-EAB5D96D9F76 Q36166095-6171DA32-7A8D-4DDD-98A2-1844751499B4 Q36415375-4ECE77AD-7250-46CB-90CB-A5969703338D Q36418328-19A85913-63DF-4777-831E-2FB743F87E93 Q37091554-CAAE4989-C809-4005-9E2A-D92A0AE31679 Q37149085-90CD9618-0869-4C0C-A063-4B80A9FB19F5 Q37244969-A11E2D49-8C86-4089-B4DF-BCEECD9A14B4 Q37390674-C84A85EA-BEE9-4149-A965-3CB60F1D9993 Q37496697-EDF019A7-DEF9-4A82-B68F-AC583FD61149 Q37550399-542E6A9C-E824-47FE-8965-7B1AF3C6A2A9 Q37714485-84BA33ED-327E-4A30-AA59-4FCCF88D7C1E Q38008241-43ABD8F8-3CBE-4AA7-AB9F-A216455F2B3C Q38099369-7ED15F3F-D033-436A-A6CF-F597922AE94D Q38109812-6474D35A-C4D2-464D-AF5B-D88EE4BCFFDD Q38611187-6E0CF475-9F26-4B24-9F75-43D06BB78038 Q38831029-A503A685-CDF0-4233-B44E-BF991277F8DD Q38920663-559A90A3-A65F-4327-9836-C869C79B6504 Q38983526-9505B5E9-7616-4896-A0D7-9CF31DA250C2 Q39449818-60762175-7084-46AA-A638-EBB7788CA78A Q40625131-096AF844-0553-4B12-8E9E-EA1737C6C0BD Q41161118-67B973D7-47E2-4BE2-A6E3-CBBB3E7F0365 Q41825673-0C187E68-7C00-41C2-8687-24AC68DC6EC0 Q41840589-17CA000A-5614-41FE-BE9C-740F5C0A819B Q41862609-38DBA2B1-22D2-4A92-9B81-7B9484137102 Q42060482-F176C4DB-D9E4-44B1-A7FC-FECCBDD1DCB2

P2860

18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.

http://www.wikidata.org/entity/Q37918311

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.

@en

18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.

@nl

type

label

18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.

@en

18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.

@nl

prefLabel

18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.

@en

18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.

@nl

P1433

Q37918311-7D7CC9E4-671B-46DD-B747-7C5670C317FC

P1476

Q37918311-3AD11BB8-8143-4CE1-A658-78F3AA1EBE80

P2093

Q37918311-1551600A-0926-4B3C-982E-90D69AF377F6

Q37918311-84DAC815-0AAF-42AD-A252-0CCAFF78E18E

Q37918311-8872142E-5A63-46FF-89DD-98AC48FC110F

Q37918311-DEA8830B-9296-4C0F-B7B0-1973AB7E359F

P2860

Q37918311-05A3CB67-D2E9-452E-AB9B-FF4038780551

Q37918311-0F0856D1-D7C5-43A7-84CA-E6C40DF19CF2

Q37918311-182A2D95-B62F-4BD0-BCFA-787AAECE66A7

Q37918311-19509C11-16B5-47E8-A45B-DAE58D093CBD

Q37918311-272E2D07-6917-4E89-9DAD-41D6CBD94FAA

Q37918311-2A262AE5-338D-4C1B-BA79-DC6C26AA4CAD

Q37918311-2E41692A-1256-4422-8934-E7A60511924D

Q37918311-30E2E3A1-EEA3-45D7-BA96-2266E9638572

Q37918311-429F86F4-2428-447A-BF74-3267B29866C2

Q37918311-43BAE4F7-18A1-44EC-BC24-BC3653AC22FA

P2888

Q37918311-25DBA884-16B7-4861-AB11-358E5EF966DC

P304

Q37918311-05C3FCAD-72FE-4FE9-99D4-57EF8E1C5C5B

P31

Q37918311-606E2E66-D64E-43A7-B840-AB0F3F1B10E7

P356

Q37918311-08EE7878-F8E2-4F8E-8BBD-E42BA212FA10

P433

Q37918311-6E74742F-677E-4C11-BEA3-4EC5593C1E33

P478

Q37918311-CC83076E-3A81-4B50-941D-53CE7F27E296

P50

Q37918311-82964E33-5655-461E-AE73-CBF0E13ADBFA

Q37918311-D81D6E0D-7ABB-4CAA-B595-EAEBF2C4B6A5

P577

Q37918311-DF5948AC-6094-4D8E-B331-646F43942D0D

P5875

Q37918311-F41A9311-6B82-4245-8695-30CEF3C9520E

P698

Q37918311-48E231D0-CB13-4F3E-952A-048DC97C0ABC

P356

P1433

Prostate Cancer and Prostatic Diseases

P1476

18F-fluorocholine for prostate cancer imaging: a systematic review of the literature

@en

P2093

A Ward

http://www.w3.org/2001/XMLSchema#string

I Rachinsky

http://www.w3.org/2001/XMLSchema#string

M Beheshti

http://www.w3.org/2001/XMLSchema#string

M Kovacs

http://www.w3.org/2001/XMLSchema#string

P2860

Studies of human tumors by MRS: a review.

Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer.

Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer.

Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials.

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

Fluorocholine PET/CT in patients with prostate cancer: initial experience.

Imaging prostate cancer: a multidisciplinary perspective.

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

Novel tracers and their development for the imaging of metastatic prostate cancer.

RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study.

P2888

P304

45-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/PCAN.2011.35

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Tarik-Zine Belhocine

P577

2011-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51574571

http://www.w3.org/2001/XMLSchema#string

P698

21844889

http://www.w3.org/2001/XMLSchema#string